1 3

AOD-9604

AOD-9604

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$65.00
$65.00
Sale Sold out
Shipping calculated at checkout.
Size

AOD-9604 — hGH Fragment (176–191) Analogue

AOD-9604 is a research peptide based on the 176–191 fragment of human growth hormone (hGH), with a stabilizing tyrosine added at the N-terminus. It’s used to explore fat-metabolism signaling in models that examine lipolysis, adipocyte biology, and energy balance—without directly using full-length hGH.

Identifiers
  • CAS: 221231-10-3
  • PubChem CID: 71300630
  • Formula / MW: C78H123N23O23S2 · ≈ 1.6 kDa (salt/form varies)
  • Core sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (hGH 176–191 analogue)
How It Works (Plain English)
  • This fragment models the C-terminal lipolytic region of hGH without engaging the full growth-hormone axis.
  • In vitro and animal models use it to track changes in fat-cell signaling, fatty-acid release, and pathway genes involved in lipid handling.
  • Because it’s a fragment, it’s useful for asking targeted questions about fat metabolism apart from broader hGH effects.
Why Researchers Use It
  • To study lipolysis and adipocyte-gene responses (e.g., HSL/ATGL pathway markers).
  • To compare fragment vs whole-axis signaling models.
  • To explore metabolic endpoints alongside incretin or endocrine tools in combination designs.

Key Studies — What Was Tested, What Changed, Why It Matters

In vitro & animal fat-metabolism models
  • What was tested: Adipocyte cultures and rodent models assessing fatty-acid release, lipase activity, and lipid-gene expression after AOD-9604 exposure.
  • What changed: Signals consistent with increased lipolysis and shifts in adipocyte gene panels were reported in several preclinical setups.
  • Why it matters: These models help isolate the fat-handling component of the GH system without the broader effects of full hGH.
Human data context (mixed findings)
  • What was tested: Early human studies explored body-fat and metabolic markers under AOD-9604 exposure.
  • What changed: Findings were inconsistent for robust fat-loss outcomes in humans.
  • Why it matters: For research design, AOD-9604 is best positioned as a mechanistic tool (pathway and biomarker studies), not as a broad efficacy agent.

Plan endpoints accordingly—focus on mechanistic readouts (gene/protein markers, lipolysis assays), not consumer-style outcomes.

Combination and delivery explorations
  • What was tested: Pairing the fragment with other metabolic cues (e.g., incretin analogues) or alternative delivery systems in preclinical contexts.
  • What changed: Model-dependent shifts in lipid metabolism and mitochondrial readouts; delivery can influence stability and uptake.
  • Why it matters: Encourages careful control of vehicle, pH, and timing when comparing single vs combination arms.

Potential Research Applications

Adipocyte & Lipolysis

  • Hormone-sensitive lipase (HSL) / ATGL activity assays
  • Glycerol/FFA release and lipid-droplet imaging

Metabolic Signaling

  • Gene panels for lipid handling (PPAR, CPT, UCPs)
  • Mitochondrial markers and energy-use readouts

Comparative Models

  • Fragment vs whole-axis peptide comparison
  • Add-on studies with incretin or endocrine tools

Synergistic Peptides (for Study Design)

Semaglutide (GLP-1)

  • Why pair: Incretin pathway for appetite/glucose control; complements lipid-handling studies.
  • Angle: Appetite + lipolysis biomarkers under combined stimuli.

Tirzepatide (GLP-1 + GIP)

  • Why pair: Dual incretin model; allows single vs dual vs fragment comparisons.
  • Angle: Glucose curves, lipid panels, and body-composition imaging (where applicable).

CJC-1295 (with DAC)

  • Why pair: Probes GH/IGF-1 cross-talk with a long-acting GHRH analogue.
  • Angle: Energy-use and lipid markers under endocrine + fragment conditions.

Design Notes

  • Separate arms clearly (fragment alone vs combo) and pre-register endpoints.
  • Control feeding schedule, ambient temperature, and activity—these shift lipolysis readouts.
  • Document formulation (vehicle, pH, light exposure) and storage for reproducibility.

Known Concerns (Context)

  • Human efficacy: Broad fat-loss claims are not supported; design studies for mechanism, not outcomes.
  • Assay sensitivity: Lipolysis measurements are timing- and temperature-sensitive; standardize rigorously.
  • General: Research use only; not for human consumption or therapeutic use.

Follow institutional SOPs for metabolic-pathway peptides and sampling schedules.

Specifications & Handling

  • Form: Lyophilized powder (lot-coded)
  • Purity: ≥ 99% (HPLC/MS verified)
  • Storage: ≤ −20 °C; protect from light/moisture
  • In solution: Aliquot promptly; avoid repeat freeze–thaw
  • Additives: None unless specified per lot
  • Packaging: Tamper-evident; research-only labeling

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

AOD-9604 Peptide Research | hGH Fragment 176–191 Analogue | Lipolysis & Adipocyte Signaling

Keywords: AOD-9604 peptide, hGH fragment 176–191, lipolysis research, adipocyte signaling, fat metabolism, Base Peptides.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.
Keep Shopping